Ultane (sevoflurane)

Indication

Ultane (sevoflurane) is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Important Safety Information

• Inhalational anesthetic agents, including Ultane, can cause malignant hyperthermia and should not be used in patients with known sensitivity to Ultane or in patients with known or suspected susceptibility to malignant hyperthermia.
• Ultane exposure should not exceed 2 MAC-hours at flow rates of 1 to <2 L/min. Fresh flow rates <1 L/min are not recommended.
• Because clinical experience in administering Ultane to patients with renal insufficiency (creatinine > 1.5mg/dL) is limited, its safety in these patients has not been established.
• Rare cases of seizures have been reported in association with Ultane use, the majority of which have occurred in children and young adults.
• Bronchospasm, laryngospasm, breathholding and increased cough have been reported in association with Ultane.
• Excessive decreases in blood pressure or respiratory depression may be related to depth of anesthesia and may be corrected by decreasing the inspired concentration of Ultane.
• Degradation of Ultane occurs in alkaline CO₂ absorbents (eg, Baralyme, soda lime) under certain conditions such as increased absorbent temperature, increased sevoflurane concentration, decreased fresh gas flow, and exposure to desiccated CO₂ absorbents. KOH containing CO₂ absorbents are not recommended for use with Ultane.